| Literature DB >> 31907994 |
Yu-Mei Mi1, Qi Qi2, Li Zhang1, Xiao-Fang Wang3, Zhi-Min Chen4, Chun-Zhen Hua1.
Abstract
BACKGROUND: Different from the diagnosis of bacterial infections, Mycoplasma pneumoniae pneumonia (MPP) is still lacking of convenient non-specific laboratory parameters.Entities:
Keywords: zzm321990Mycoplasma pneumoniaezzm321990; C3; children; pneumonia; sialic acid
Year: 2020 PMID: 31907994 PMCID: PMC7083476 DOI: 10.1002/jcla.23078
Source DB: PubMed Journal: J Clin Lab Anal ISSN: 0887-8013 Impact factor: 2.352
General information of the control group (89 cases) and MPP group (125 cases)
| Gender | Age (y) | Days in Hospital | Fever days | Days between two detections | |||
|---|---|---|---|---|---|---|---|
| Male | Female | M/F ratio | |||||
| Control | 47 | 42 | 1.12:1 | 5.6 ± 3.1 | 7.5 ± 2.1 | 4.9 ± 2.9 | 5.0 ± 1.7 |
| MPP | 73 | 52 | 1.4:1 | 6.2 ± 3.1 | 9.5 ± 2.1 | 5.8 ± 3.1 | 5.5 ± 1.7 |
Comparisons between the control group (89 cases) and MPP group (125 cases) white blood cell count, neutrophilic granulocyte (NEUT) count, and sCRP in acute phase (A.S) and recovery phase (R.S)
| WBC (×109) | NEUT (×109) | sCRP (mg/L) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A.S | R.S |
|
| A.S | R.S |
|
| A.S | R.S |
|
| |
| Control | 9.07 ± 4.17 | 7.25 ± 1.60 | 3.82 | <.001 | 5.48 ± 3.66 | 3.43 ± 1.27 | 4.94 | <.001 | 19.16 ± 3.83 | 4.54 ± 0.97 | 3.46 | <.001 |
| MPP | 7.16 ± 2.71 | 7.44 ± 2.44 | 0.63 | .53 | 4.28 ± 2.00 | 3.86 ± 1.95 | 1.95 | .07 | 22.02 ± 2.38 | 5.43 ± 0.92 | 6.19 | <.001 |
|
| 3.80 | 0.821 | – | – | 2.80 | 1.96 | – | – | 0.67 | 0.61 | – | – |
|
| 0.001 | 0.413 | – | – | 0.006 | 0.052 | – | – | 0.51 | 0.55 | – | — |
Comparisons between the control group (89 cases) and MPP group (125 cases) levels of sialic acid, IgG, C3, and C4 in acute phase (A.S) and recovery phase (R.S)
| Sialic acid (mg/L) | IgG (g/L) | C3 (g/L) | C4 (g/L) | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| A.S | R.S |
|
| A.S | R.S |
|
| A.S | R.S |
|
| A.S | R.S |
|
| |
| Control | 79.2 ± 17.2 | 77.9 ± 15.3 | 0.40 | .693 | 8.76 ± 2.92 | 9.04 ± 2.87 | 0.65 | .52 | 1.20 ± 0.29 | 1.17 ± 0.27 | 0.86 | .39 | 0.31 ± 0.10 | 0.27 ± 0.09 | 2.98 | .003 |
| MPP | 88.0 ± 14.5 | 83.7 ± 13.9 | 2.81 | .005 | 9.00 ± 2.68 | 9.71 ± 2.69 | 2.07 | .04 | 1.37 ± 0.30 | 1.26 ± 0.22 | 3.23 | .001 | 0.34 ± 0.12 | 0.23 ± 0.10 | 7.86 | <.001 |
|
| 4.17 | 2.79 | – | – | 0.60 | 2.61 | – | – | 4.06 | 2.78 | – | – | 1.91 | 2.87 | – | – |
|
| <0.001 | 0.006 | – | – | 0.548 | 0.108 | – | – | <0.001 | 0.006 | – | – | 0.057 | 0.005 | – | – |
Figure 1The analysis of the correlations between sialic acid and sCRP, C3, C4, or IgG at the acute and recovery stage in MPP